CURRICULUM VITAE
Name:
Place of Birth:
Education:
Charles H. Evans, Jr., M.D., Ph.D
Orange, New Jersey
1958 Graduated from Columbia High School, Maplewood, New Jersey
1962 B.S., (Biology), Union College, Schenectady, New York
1969 M.D., University of Virginia, Charlottesville, Virginia
1969 Ph.D., (Microbiology-Immunology), University of Virginia
Thesis: Fluorescein Isothiocyanate Probing of Human Immunoglobulin G
Honors: Alpha Omega Alpha (National Medical Scholastic Honor Society)
Sigma Xi (National Scientific Honor Society)
Raven Society (University of Virginia Scholastic Honor Society)
Whitehead Fellow in Anatomy, 1964-1965
Medical Scientist, Life Insurance Medical Research
Fund, 1967-1969
Postgraduate Training:
Intern in Pediatrics, University of Virginia Medical Center, Charlottesville,
Virginia, 1969-1970.
Resident in Pediatrics, University of Virginia Medical Center, Charlottesville,
Virginia, 1970-1971.
Research Associate, National Cancer Institute, National Institutes of Health,
Bethesda, Maryland, 1971-1974.
Major Specialty Training:
Pediatrics, Immunology & Microbiology, Oncology (Carcinogenesis), Medical
Biotechnology, Health Science and Services Research, Administration &
Governance
Professional Licensure, Certification, and Continuing Education:
License to Practice Medicine and Surgery in the Commonwealth of Virginia,
1969-present.
Diplomat, National Board of Medical Examiners, 1970.
Fellow, American Academy of Medical Administrators, 1993; Credentialed health
services administrator, 1996.
Professional Experience:
2002-present
Professor , School of Nursing and Health Studies, Georgetown University,
Washington, D.C. Health Studies Science Track Coordinator 2002-2003;
Chair, Department of Human Science, 2003-present.
1998-2002
Executive Staff, Institute of Medicine, The National Academies (Science,
Engineering and Medicine), Washington, D.C. Scholar-in-Residence,
2001-2002. Sr. Adviser, Biomedical and Clinical Research, 1999-2001.
Head, Health Sciences Section, 1998-1999. . Analytical studies of
research needs and national policy in setting biomedical research
priorities, patient protection institutional review board accreditation and
CV CH Evans 2
Professional Experience: (continued)
function, equity distribution of organ donation and allocation for
transplantation recipients, chemical and biological terrorism
preparedness, disparities in cancer research and care, environmental
justice, biomedical research ethics, strategies for small number
participant clinical research trials, and a vision for space medicine during
travel beyond Earth orbit.
1976-1998
Chief of the Tumor Biology Section, National Cancer Institute.
Planned, executed and administered an investigator initiated basic
science biomedical research program in the etiology and inhibition
of cancer. As a principal investigator  recruited, trained and supervised research students and
postdoctoral fellows.
 initiated national and international scientific research collaborations
 provided expertise in evaluation of national and international
research
 authored/co-authored >100 research publications
 discovered the cytokine leukoregulin
 see committee and advisory board service below for details of
career progression
1974-1976
Research Scientist, National Cancer Institute, National Institutes of
Health,
Bethesda, Maryland.
Service in the Uniformed Services of the United States:
Medical Officer United States Public Health Service Commissioned Corps. Active
duty 1971-1998. Retired, March 1998. Current rank: Captain, USPHS-ret.
Service on Scientific and Community Committees and Advisory Boards:
Georgetown University
Middle States Periodic Review Steering Committee, 2006-present.
Executive Faculty Committee on Intellectual Life, 2006-2007.
Fellowships Endorsement Committee, 2004-present.
Provost’s Undergraduate Learning Initiative, 2003-2008.
Board of Directors, Center for New Discoveries in Learning and Scholarship
(CNDLS) 2003-2007.
Provost’s Center for Science Advisory Committee, 2002-2003.
Center for Clinical and Translational Science at Georgetown University
MedStar Research Institute/Medstar Health and Virginia Tech
Planning Committee, 2006-2008.
Committee on Medical Education, Georgetown University Medical School,
2005-present.
School of Nursing & Health Studies Research Council, 2002-present.
School of Nursing and Health Studies Committee on Students, 2002present.
CV CH Evans 3
Other Professional
National Aeronautics and Space Administration (NASA) Critical Care
Medicine Working Group, 2000-2005. Space Surgeon Requirements
Working Group, 2002-2005.
American Academy of Medical Administrators, Continuing Certification
Credentialing Standards Committee, 2003-2006.
National Dental Research Centers Study Section, National Institute of
Craniofacial Disorders and Dental Research, 1998-1999.
Tumor Biology and Clinical Studies Section, Breast Cancer Research
Program, State of California, Office of the President, University of
California, 1995.
Special Emphasis Review Panel, National Institute of Dental Research,
Regional Research Centers for Minority Oral Health Phase II, 1995.
Tumor Biology and Therapy Study Section, Tobacco-Related Disease
Research Program, State of California, Office of the President, University
of California, 1993-1994.
Associate Editor, Journal of Cellular Biochemistry, 1989-present.
Board of Trustees, Suburban Hospital Healthcare System, Bethesda,
Maryland. Advisory Council, 1987-1988; Trustee, 1988-1997. Trustee
Emeritus 1997-present. Chairman, Governance Committee, 1989-1992.
CEO Search Committee, 1992. Executive Personnel Committee, 19891997. Hospital Medical Ethics Committee, 1993-1997. Chairman, Medical
Affairs Committee, 1994-1997.
Editorial Board, Journal of the National Cancer Institute, 1981-1993.
Editorial Board, THE EXECUTIVE, journal of the American Academy of
Medical Administrators, 1989-1992.
National Cancer Institute Laboratory Specialist Promotion Panel, 980-1985;
Chairman, 1983-1985.
Control of Chemical and Biological Hazards in the Laboratory, Division of
Safety, NIH; Course Instructor, 1980-1983.
National Cancer Institute Director's Immunology Working Group, 1977-1980.
Carcinogenesis Collaborative Program Management Group, National
Cancer Institute, 1977-1978.
Civic and Community
Board of Directors, Meadowkirk Meeting, Camp and Retreat Ministry,
National Capital Presbytery, Washington, DC, Chairman 2008Board of Directors, The First Tee Montgomery, 2002-2005
Arts and Sciences College Board of Trustees (formerly Alumni Council),
University of Virginia, 1987-1997. Vice-President 1993-1997; Publications
Committee Chairman, 1988-1993. Emeritus Trustee, 1998-present.
Rotary Club of Bethesda-Chevy Chase, 1981-present; President, 19861987. Board of Directors, Bethesda-Chevy Chase Rotary Club Foundation,
Inc., 1983-present; President, 1987-1988, 1997-1998.
Trustee and Ruling Elder, Bradley Hills Presbyterian Church, Bethesda,
Maryland, 1975-78, 1986-1989, 1997-2002, 2006-present. Chair,
Worship & Arts Lay Ministry 2006-present, Education & Nurture Lay
Ministry, 1997-2002. Board of Directors, Bradley Hills Presbyterian
Church Nursery School, Bethesda, Maryland, 1978-1995; Chairman,
1987-1995.
CV CH Evans 4
Civic and Community Service (continued):
Board of Governors, Azalea Society of America, 1983-1989. National
Convention Chairman, 1983, 1988. Editor-in-Chief, The Azalean,
Journal of the Azalea Society of America, 1983-1988.
Distinguished Service Award, 1989. President, Brookside Gardens
Chapter, 2002- present.
Washington Committee of the Pro Musicis Foundation, 1986-1989.
Boy Scouts of America, National Capital Area Council Exploring Committee,
Health and Safety Chairman, 1990-1992
Professional Awards and Honors:
Innovative Teaching Award, Georgetown University School of Nursing and
Health Studies, 2004.
Fellow, American Association for the Advancement of Science, 1998.
United States Public Health Service Outstanding Service Medal for research
leadership in defining immune defenses against cancer, 1996.
United States Public Health Service Unit Commendation for service interviewing
applicants to the Uniformed Services University of the Health Sciences, 1992.
Sir Henry Wellcome Medal and Prize, 1990.
United States Public Health Service Commendation Medal for discovery of the
immunologic hormone (cytokine) leukoregulin, 1985.
John Horsley Memorial Prize for investigation in the fundamental medical
sciences, University of Virginia, 1982.
United States Public Health Service Citation for "sustained high performance in
achievement of scientific investigations and program objectives," 1980.
Sigma Xi, Associate Member 1967, Full Member 1974.
Alpha Omega Alpha, 1964.
Funded Research: (32 years of continuous support as a principal investigator)
Evans, C., (2005-present). P.I., Pathways to Success; Goldman Sachs Foundation,
$260,000.
Evans, C., (2002-2005). P.I., Community Building to Promote Biomedical Health
Careers; National Center Research Resources, National Institutes of Health,
$300,000.
Evans, C. (1999-2001). P.I., Creating a Vision for Space Medicine during Travel
Beyond Earth Orbit; U.S. National Aeronautics and Space Administration,
$1,400,000.
Evans, C. (1999-2000). P.I., Strategies for Small Number Participant Clinical
Research Trials; U.S. National Aeronautics and Space Administration, $250,000.
Evans, C. (1999). P.I., National Town Meeting on Research Misconduct; U.S.
Department of Health and Human Services, $50,000.
Evans, C. (1974-1998). P.I., Immunobiology of Carcinogenesis; National Cancer
Institute, $5,000,00 over 25 years.
Inventions reduced to patent and practice:
Leukoregulin, an anti-tumor lymphokine and its therapeutic uses. U.S. patent
4,849,506.
Leukoregulin Anti-viral therapy. U.S. patent 5,368,853.
Leukoregulin Anti-Herpes Treatment. U.S. patent 5,529,771.
CV CH Evans 5
Membership (active) in Professional and Scientific Organizations:
Academy of Medicine of the District of Columbia
American Academy of Medical Administrators, Elected a Fellow, November 1993.
Credentialed Fellow in Medical Administration, 1996.
American Association for the Advancement of Science, Elected a Fellow, 1998.
American Association for Cancer Research
American Association of Immunologists
American Society for Cell Biology
Clinical Immunology Society (Charter Member).
Cosmos Club, Washington, D.C.
Current Research and Scholarship
P.I. on study of effective means to build interest of talented rural American high
school youth in pursuing biomedical science as a career. 2002—present.
Co-P.I. with Michael V. Relf, Ph.D., Chair of the Department of Professional Nursing
at Georgetown University in determining the incidence of HIV-1 gene resistance to
antiretroviral therapy in treatment naïve (untreated) individuals in the metropolitan
Washington , D.C., region. 2005-present.
Faculty adviser and founder, annual Georgetown University Undergraduate
Student Research Conference, 2002-present.
Faculty adviser and founder, on-line undergraduate Georgetown University Journal of
Health Science, 2002-present.
Development of undergraduate digital senior health science theses in collaboration
with the Electronic Thesis and Dissertation Initiative of Digital Georgetown at
Georgetown University. 2005-present.
Current Teaching and Presentation Activities:
Courses designed and taught (all undergraduate at Georgetown University).
Language of Health and Disease, 3 credit hours, Spring 2003, 2004
Physiological Adaptation to Space Flight and other Extreme Environments,
3 credit hours, Fall and Spring 2003, 2004, 2005, 2006
Epidemiologic Applications to Population Health, 3 credit hours, Spring 2004
Health Promotion Disease Prevention Experiential Laboratory, 1 credit hour,
Spring 2003, 2004, 2005, 2006
Communicating Science Seminar, 1 credit hour, Fall and Spring 2002,2003
2004, 2005, 2006
Contemporary Issues in Science Seminar, Fall and Spring 2004, 2005, 2006
Recent National Presentations
Community Building to Promote Careers in Biomedical Science. CH Evans,
MI Klopf and AE French, AAAS National Meeting, February 2005 and
American Society for Cell Biology Eucation Initiative Forum, December 2005.
Human Simulation in Discovering Limits of Human Physiological Adaptation.
CH Evans and RC Perez, AAAS National Meeting, February 2005.
CV CH Evans 6
Organizer/Chairperson of National/International Scientific Meetings:
Organizer, Future Directions for Research with Small Number Participant
Populations, National Academy of Sciences, September 2000.
Organizer, Medicine in Extreme Environments, National Academy of Sciences, July
2000.
Organizer, National Town Meeting to discuss the proposed New Common Federal
Definition of Research Misconduct, National Academy of Sciences, September
1999.
Co-organizer, XIX International Congress of Virology workshop: Cytokines,
Interferons and Virokines in Virus Diseases, Glasgow, Scotland, August 6-13,
1993.
Co-organizer, 1992 Keystone Symposium: Cytokines in Growth, Development and
Pathogenesis, Taos, New Mexico, February 1-8, 1992.
Organizer, Biomolecular Recognition and Targeting Strategies in the Prevention
And Treatment of Disease, University of Virginia, October 23-25, 1991.
Co-organizer, VIII International Congress of Virology Workshop: Lymphokines and
other Mediators in Virus Infections, Berlin, August 26-31, 1990.
Co-organizer, 1990 American Society of Microbiology Symposium: Cytokines and
Drugs: Biotherapies for Infectious Diseases, Anaheim, California, May 14, 1990.
Co-organizer, 1990 UCLA Symposium: Molecular Pathways of Cytokine Action,
Park City, Utah, January 27-February 3, 1990.
Co-organizer 1988 UCLA Symposium: Mechanisms of Action and Therapeutic
Application of Biologicals in Cancer and Immunodeficiency Diseases, Keystone,
Colorado, April 23-30, 1988.
Organizer, 1987 UCLA Community Resource Coordination Workshop:
Biotechnology Products for Treatment of Cancer and Immunodeficiency
Diseases, Keystone, Colorado, April 3-4, 1987.l 23-30, 1988.
Co-organizer, 1987 UCLA Colloquium: Biotechnology Products in Cancer,
Therapy, Lake Tahoe, California, March 1-4, 1987.
Major Invited Biomedical National and International Lectures:
Plenary speaker, American Society of Cell Biology annual meeting, San
Francisco, CA, December 13, 2005, “Community Building to Promote Careers
In Biomedical Science”
Keynote speaker, Medicine in 21st Century Symposium, New Jersey Medical
School, Newark, NJ, June 4, 1997. “History of cytokines.”
Plenary Speaker, Burroughs Wellcome Research Foundation Symposium on
Innovations in Therapy of Human Viral Diseases, Research Triangle Park, NC,
December 6-9, 1992. "Cytokine molecular target interactions and the design of
antiviral biotherapeutics."
Plenary Speaker, Keystone Symposium on Cytokines in Growth, Differentiation
and Pathogenesis of Disease, Taos, NM, February 1-8, 1992.
"Cytokines as Anti-viral Agents."
Plenary Speaker, Biomolecular Recognition and Targeting Strategies in
Prevention and Treatment of Disease, University of Virginia, Charlottesville,
VA, October 22-25, 1991. "Cytokine modulation of target cell plasma
membrane sensitivity to lymphocyte destruction."
CV CH Evans 7
Major Invited Biomedical National and International Lectures: (continued)
Plenary Speaker, 1990 American Society of Microbiology Symposium on
Cytokine and Drugs: Biotherapies for Infectious Diseases, Anaheim, CA,
May 14, 1990. "Leukoregulin: Potential therapeutic agent for infections &
malignancies."
Plenary Speaker, UCLA Symposium on Molecular Pathways of Cytokine Action,
Park City, Utah, January 27-February 3, 1990. "Lymphokine enhancement of
drug uptake."
Speaker, 1989 American Cancer Society Science Writers Seminar, Irvine,
California, April 2-5, 1989. "Leukoregulin enhancement of anti-cancer
pharmacologic action- A new approach to drug delivery."
Plenary Speaker, UCLA Symposium on Mechanism of Action and Therapeutic
Application of Biologicals in Cancer and Immunodeficiency Diseases,
Keystone, CO, April 1988. "Biological and molecular characteristics of
leukoregulin action."
Speaker, Second National Conference on Immunity against Cancer,
Williamsburg, Virginia, November 9-11, 1987. "Leukoregulin."
Plenary Speaker, UCLA Symposium on Membrane-Mediated Cytotoxicity, Park
City, UT, March 1986. "Leukoregulin, lymphotoxin, and interferon
transmembrane signaling and regulation of cell growth"
Speaker, Workshop on Lymphotoxin, Tumor Necrosis Factor, and T, NK and
Macrophage Cytotoxic Factors sponsored by the Cancer Research Institute at
Memorial Sloan-Kettering Cancer Center, NY, December 1984, "Cell source,
biological activities and specificity of lymphotoxin. "
Plenary Speaker, 10th Anniversary of Flow Cytometry in Immunology, National
Institutes of Health, Bethesda, MD. April 4, l984. "Identification of
leukoregulin as an intrinsic mediator of natural killer cytotoxicity."
Lecturer, Hauptseminar Biochemie, Biochemische Institute, Albert-Ludwigs
Universitat, Freiburg im. Briesgau, Germany, July 1983. "Biochemica
l properties and hormonal action of lymphotoxin."
Lecturer in Experimental Oncology, Medicinische klinik A, University of
Dusseldorf, Dusseldorf, Germany, June 1983. "Lymphokines, homeostasis,
and carcinogenesis."
Speaker, George Washington University 1983 Spring Symposium, "Thymic
Hormones and Lymphokines," National Academy of Sciences, Washington,
DC, June 1983. "The anti-cancer action of lymphotoxin."
Consultant and speaker, Health Careers Conference on "Contemporary
Perspectives in Biomedical Careers," Johnson C. Smith University,
Charlotte, NC, March 1982.
Medical Grand Rounds speaker and Visiting Professor of Medicine, University of
Wisconsin, Madison, WI, June 1981. "Lymphotoxin - an immunologic
hormone with anticarcinogenic and antitumor activity."
Speaker, 1980-1981 Comprehensive Cancer Center Seminar Program,
Pennsylvania State University Medical Center, Hershey, PA,
November 1980. "The regulation of cell transformation by chemical and
physical carcinogens."
1980 Century Forum Lecturer and Visiting Professor of Medicine, University of
Vermont, College of Medicine, Burlington, VT, November 1980. "Cancer
and immunity: prevention of carcinogenesis by the normal immune system."
CV CH Evans 8
Major Invited Biomedical National and International Lectures: (continued)
Speaker, International Workshop on Short-Term Tests for Chemical
Carcinogens, University of British Columbia, Vancouver, Canada, August,
1979. "In vitro mammalian cell transformation for identification of carcinogens,
cocarcinogens and anticarcinogens."
Speaker, Advances in Cancer Biology I: In Vitro Carcinogenesis, Given Institute
of Pathobiology, Aspen, Colorado, July, 1976. "Neoplastic transformation by
chemicals of guinea pig fetal cells in culture."
Speaker, Third Collaborative Conference, Carcinogenesis Program, Division of
Cancer Cause and Prevention, National Cancer Institute, Orlando, Florida,
February, 1975. "Colony inhibition mediated by nonimmune leukocytes in vitro
and skin reactivity in vivo as indices of tumorigenicity in guinea pig cultures
transformed by chemical carcinogens."
Speaker, XI International Cancer Congress, Florence, Italy, October, 1974.
"Properties of cells from different species accompanying chemical carcinogen
induced transition to the neoplastic state."
Speaker, Twenty-fourth Annual Meeting of the Tissue Culture Association,
Boston, Massachusetts, June, 1973. "Chemical carcinogen induced
neoplastic transformation in vitro."
Speaker, Conference on Carcinogenesis Testing in the Development of New
Drugs National Academy of Sciences, Washington, D.C., May, 1972. Chemical
carcinogenesis of mammalian cells in culture: applicability to the evaluation of
new drugs."
Publications in print and on-line:
120 articles, books, audio-visuals.
20 book chapters. 123 abstracts.
Abstracts are not included in the listing below
1.
Boyd, A.C., Herzberg, E.M., Marshall, M.M., Lamparello, N.A., DeLeon, M.A.,
Porter, A., Evans, C.H. Jr., Doshi, S, Shahkolahi, A, Dekker, D, Relf, M:
Antiretroviral drug resistance among treatment-naïve HIV-1 infected persons in
Washington, DC. AIDS Patient Care and STDS 22: 445-448, 2008.
2.
Evans, C.H. Saving the Creation. Sermon preached on August 26, 2007.
http://www.bradleyhillschurch.org/article98488.htm
3.
Lehnes, K. Winder, A.D., Alfonso, C., Kasid, N., Simmoneaux, M., Summe, H.,
Morgan, E., Iann, M.C., Duncan, J., Eagan, M., Tavaluc, R., Evans, C.H. Jr.,
Russell, R., Wang, A., Hu, F., Stoica, A.: The Effect of estradiol on in vivo
tumorigenesis is modulated by the human epidermal growth factor receptor
2/phosphatidylinositol 3-kinase.Akt1 pathway. Endocrinology 148:1171-1180,
2007.
4.
Cesari, W.A., Caruso, D.M., Zyka, E.L., Schroff, S.T., Evans, C.H. Jr., Hyatt,
J.K.: Study of physiological responses to acute carbon monoxide exposure with
a human patient simulator. Adv. Physiol. Educ. 30: 242-247, 2006.
CV CH Evans 9
5.
Evans, C.H. Spirituality and science converging in thin places. Sermon preached
on August 13, 2006. http://www.bradleyhillschurch.org/article51865.htm 2006.
6.
Evans ,C.H., Klopf, M.I., French A.L.: Community Building to Promote Careers in
Biomedical Science. American Society of Cell Biology, Education Initiative
Forums. http://www.ascb.org/newsfiles/charles_evans.swf 2006.
7.
Klopf, N., McNeil, S., Evans, C.: The Biomedical Institute Program.
Documentary digital video at http://lumen.georgetown.edu/faculty/che3/,
Georgetown University, 2005.
8.
McSwain, N.E., Bogomolov, A.L., Cantrill, V.V., Chapman, S.V., Comtois, G.,
Damann, J., Davies, V., Doerr, H., Evans, C., Fisher, C., Gray, G., Gloss, D.,
Jacobs, L.M., Jones, J.A., Kuklinski, P., Legome, E., Lowery, D.W., Marx, J.A.,
Mercer, S., Morgun, V.V., Nicogossian, A.E., Pool, S.L., Pons, P. , Putcha,,L.,
Sawin, C.F., Sekiguchi, C., Tintinalli, J., Van Meter, K., White, R., Williams, D.R.,
Williams, R. Resuscitation and Critical Care in Space. NASA Technical Report
Series, Johnson Space Center, Houston, Texas, February 2003, 94 pp.
9.
Ball, J.R., Evans, C.H. Jr. (Eds.): Safe Passage: Astronaut Care for Exploration
Missions. Washington, D.C., National Academy Press, 2001. [United States
Library of Congress holding call number RC1135.I576 2001].
10.
Evans, C.H. Jr., Ildstad, S.T. (Eds.): Small Clinical Trials: Issues and Challenges.
Washington, D.C., National Academy Press, 2001. [United States Library of
Congress holding call number R853.C55 S58 2001].
11.
Gaiotti D., Chung,J., Iglesias M., Nees M., Baker P.D., Evans C.H., Woodworth
C.D.: Tumor necrosis factor-alpha promotes human papillomavirus (HPV) E6/E7
RNA expression and cyclin-dependent kinase activity in HPV- immortalized
keratinocytes by a ras-dependent pathway. Mol. Carcinogenesis 27:97-109,
2000.
12.
Young D.A., Evans, C.H., Smith, T.J.: Leukoregulin induction of protein
expression in human orbital fibroblasts: Evidence for anatomical site-restricted
cytokine-target cell interactions. Proc. U.S. Natl. Acad. Sci. 95:8904-8909, 1998.
13.
Evans, C.H.: Cytokines and chemokines: Molecular keys to growth and
differentiation. The Chemist 74:10-16, 1997.
14.
Evans, C.H.: How to reduce the risk of severe infection in asplenic patients.
Consultant 37:1166-1167, 1997.
15.
Evans, C.H.: Virus cytokine interactions. In: Bertino, J.R., ed. Encyclopedia of
Cancer. Academic Press, Inc. New York, 1997, pp. 1995-2002.
CV CH Evans 10
16.
Wang, H., Cao, H.J., Winn, V.D., Rezanka, L.J., Frobert, Y., Evans, C.H.,
Sciaky, D., Young, D.A., Smith, T.J.: Leukoregulin induction of prostaglandin
endoperoxide H synthase-2 in human orbital fibroblasts: an in vitro model for
connective tissue inflammation. J. Biol. Chem. 271:22718-22728, 1996.
17.
Evans, C.H: Cytokines and viral anti-immune genes. Stem Cells 14:177-184,
1996.
18.
Evans, C.H.: Cytokine and related host defense virus interactions. Drug News
and Perspectives. 8:469-474, 1995.
19.
Evans, C.H., Lee, T.S., Flugelman, A.A.: Spermine directed immunosuppression
of cervical carcinoma cell sensitivity to a majority of lymphokine activated killer
(LAK) lymphocyte cytotoxicity. Natural Immunity 14:157-163, 1995.
20.
Hogg, M.G., Evans, C.H., Smith, T.J.: Leukoregulin induces plasminogen
activator type-1 in human orbital fibroblasts. Am. J. Physiol. 269:359-366, 1995.
21.
Zimonjic, D.B., Rezanka, L.J., Evans, C.H., Polymeropoulos, M., Trent, J.M.,
Popescu, N.C.: Mapping of the immune interferon gamma gene (IFNG) to
chromosome band 12q14 by fluorescence in situ hybridization. Cytogenet and
Cell Genet. 71:247-248, 1995.
22.
Smith, T.J., Wang, H., Evans, C.H.: Leukoregulin is a potent inducer of
hyaluronan synthesis in cultured orbital fibroblasts. Am. J. Physiol. 268:C382388, 1995.
23.
DiPaolo, J.A., Woodworth, C.D., Evans, C.H.: Cytokines inhibit human
papillomavirus transcription and enhance cell sensitivity to lymphocyte killing. In:
Monsonego, J., ed. Papillomavirus in Human Pathology. Rome: Serono
Symposia Publications, pp449-457, 1995.
24.
Mauviel, A., Lapière, Halcin, C., Evans, C.H., Uitto, J.: Differential Cytokine
Regulation of Type I and Type VII Collagen Gene Expression in Cultured Human
Dermal Fibroblasts. J. Biol. Chem., 269:25-28, 1994.
25.
Evans, C.H.: Cytokines: Molecular keys to homeostasis, development and
pathophysiology . J. Cell. Biochem. 54:1-3, 1993.
26.
Mauviel, A., Chgen, Y., Dong, W., Evans, C.H., Uitto, J.: Transcriptional
interactions of transforming growth-factor-inflammatory cytokines.
Current Biol., 3:822-831, 1993.
27.
Evans, C.H., Flugelman, A.A., DiPaolo, J.A.: Cytokine modulation of immune
defenses in cervical cancer. Oncol. 50:245-251, 1993.
CV CH Evans 11
28.
Mauviel, A., Kähäri, V., Chen, Y.Q., Kurkinen, M., Evans, C.H., Uitto, J.:
Transcriptional activation of fibroblast stromelysin-1 and collagenase gene
expression by a novel lymphokine, leukoregulin. Trans. Assn. Amer. Phys.
105:100-109, 1992.
29.
Evans, C.H., Baker, P.D.: Decreased expression of P-glycoprotein in multidrug
sensitive and resistant human myeloma cells induced by the cytokine
leukoregulin. Cancer Res. 52:5893-5899, 1992.
30.
Mauviel, A., Kähäri, V., Kurkinen, M., Evans, C.H., Uitto, J.: Leukoregulin, a Tcell derived cytokine, up-regulates stromelysin-1 gene expression in human
dermal fibroblasts. J. Cell. Biochem. 50:53-61, 1992.
31.
Mauviel, A., Reitamo, S., Remitz, A., Lapière,J., Ceska, M., Baggiolini, M., Walz,
A., Evans, C.H., Uitto, J.: Leukoregulin, a T-cell derived cytokine, induces
interleukin-8 gene expression and secretion in human skin fibroblasts. J.
Immunol. 149:2969-2976, 1992.
32.
Mauviel, A., Evans, C.H., Uitto, J.: Leukoregulin down-regulates type I collagen
mRNA levels and promoter activity in human dermal fibroblasts, and counteracts
the up-regulation elicited by transforming growth factorBiochem. J. 284:629632, 1992.
33.
Mauviel, A., Kähäri, V., Evans, C.H., Uitto, J.: Transcriptional activation of
fibroblast collagenase gene expression by a novel lymphokine, leukoregulin. J.
Biol. Chem. 267:5644-5648, 1992.
34.
Woodworth, C.D., Lichti, U., Simpson, S., Evans, C.H., DiPaolo J.A.:
Leukoregulin and interferon gamma inhibit human papillomavirus (HPV) type 16
gene transcription in HPV-immortalized human cervical cells. Cancer Res.
52:456-463, 1992.
35.
Fishelson, Z., Shlanger, S., Bomstein, Y., Evans, C.H.: The human lymphokine
leukoregulin induces cell resistance to complement-mediated lysis. Immunol.
Lett. 32:35-42, 1992.
36.
Evans, C.H., Furbert-Harris, P.M., Flugelman, A.A., Woodworth, C.D., DiPaolo,
J.A.: Synergistic regulation of LAK lymphocyte cytotoxicity by combination
cytokine and cisplatin treatment. Combination Therapies. A.L. Goldstein and E.
Garaci (Eds.), Plenum Press, New York, 1992, pp. 237-244.
37.
Yan, B., Baker, P.D., Evans, C.H., Marsh, J.W.: Influence of endogenous thy1.1
cells upon the efficacy of an anti-thy1.1 antibody-diphtheria toxin conjugate.
Bioconjug. Chem. 2:207-210, 1991.
CV CH Evans 12
38.
Hooks, J.J., Detrick, B., Evans, C.H.: Leukoregulin, a novel cytokine enhances
the anti-herpesvirus actions of acyclovir. Clin. Immunol. Immunopath. 60:244253, 1991.
39.
Mauviel, A., Rédini, F., Hartmann, D.J., Pujol, J., Evans, C.H.: Modulation of
human dermal fibroblast extracellular matrix metabolism by the lymphokine
leukoregulin. J. Cell Biol. 113:1455-1462, 1991.
40.
Detrick, B., Evans, C.H., Chader, G.J., Hooks, J.J.: Cytokine-induced
modulation of cellular proteins in retinoblastoma. Analysis by flow cytometry.
Investig. Opthalmol. & Visual Sci. 32:1714-1722, 1991.
41.
Evans, C.H., Hooks, J.J., Detrick, B.: Leukoregulin: a new biotherapeutic
cytokine in the search for more effective anti-viral pharmacologic agents. Mil.
Med. 156: 155-159, 1991.
42.
Evans, C.H.: Growth and differentiation - fulfilling the dream. J. Cell Biochem.
45: 1-2, 1991.
43.
Evans, C.H., Baker, P.D.: Leukoregulin enhancement of tumor inhibitory drug
uptake. In: Cytokines in Hemopoiesis, Oncology and Aids, Eds. M. Freund, H.
Link, and K. Welte. Springer Verlag, Berlin, 1990, pp. 331-336.
44.
DiPaolo, J.A., Woodworth, C.D., Furbert-Harris, P.M., Evans, C.H.:
Immunomodulation of HPV16 immortalized exocervical epithelial cells. In Gross,
E., Jabolonska, S., Pfister, H., and Stegner, H-E. (Eds.): Genital Papillomavirus
Infections: Advances in Modern Diagnosis and Therapy. Springer, BerlinHeidelberg-New York, 1990, pp. 283-299.
45.
Slingluff, C.L. Jr., Seigler, H.F., Darrow, T.L., Evans, C.H.: Implications of
leukoregulin to autologous tumor specific human T-cell populations. J. Biol.
Resp. Modifers 9:387-394, 1990.
46.
Evans, C.H., Furbert-Harris, P.M., Woodworth, C.D., DiPaolo, J.A.: Lymphokine
modulation of HPV16 transfected cervical epithelial cell sensitivity to natural killer
lymphocyte cytotoxicity. In: Papillomaviruses. UCLA Symposia on Molecular
and Cellular Biology, New Series, Volume 124, Eds. P. Howley and T. Broker.
Alan R. Liss, Inc., New York, 1990, pp. 145-155.
47.
Evans, C.H.: Commitment to Quality - The Pledge to total quality management
at DHHS. Executive, 28: (2):3, 1990.
48.
Hooks, J.J, Chader, G., Evans, C.H., Detrick, B.: Interferon-gamma enhances
the expression of retinal S-antigen, a specific neuronal cell marker. J.
Neuroimmunol., 26:245-250, 1990.
CV CH Evans 13
49.
Barnett, S.C., Evans, C.H.: Influence of extracellular calcium on cell
permeablization and growth regulation by the lymphokine leukoregulin. J. Cell.
Biochem., 43:89-101, 1990.
50.
Evans, C.H., Barnett, S.C., Gelleri, B.A., Furbert-Harris, P., Sheehy, P.A.,
Barker, J.L., Baker, P.A., Wilson, A.C., Farley, E.K., D'Alessandro, F.: Biological
and molecular characteristics of leukoregulin action. In Groopman, J.E., Evans,
C.H. and Golde, D.W. (Eds.): Mechanisms of Action and Therapeutic
Applications of Biologicals in Cancer and Immune Deficiency Disorders. New
York, N.Y., Alan R. Liss, Inc., 1989, pp. 315-329.
51.
Groopman, J.E., Golde, D.W., Evans, C.H. (Eds.): Mechanisms of Action and
Therapeutic Applications of Biologicals in Cancer and Immune Deficiency
Disorders. New York, N.Y,, Alan R. Liss, Inc., 1989. [United States Library of
Congress holding call number RC271.B53 M43 1989].
52.
Furbert-Harris, P., Evans, C.H.: Leukoregulin up-regulation of tumor cell
sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Cancer Immunol. Immunother., 30:86-91, 1989.
53.
Furbert-Harris, P.M., Evans, C.H., Woodworth, C.D., DiPaolo, J.A.: Loss of
leukoregulin up-regulation of NK but not LAK lymphocytotoxicity in human
papilloma virus 16 DNA-immortalized cervical epithelial cells. J. Natl. Cancer
Inst., 81:1080-1085, 1989.
54.
Evans, C.H., Wilson, A.C., Gelleri, B.A.: Preparative isoelectric focusing in
ampholine electrofocusing columns versus immobiline polyacrylamide gel for the
purification of biologically active leukoregulin. Anal. Biochem. 177:358-363,
1989.
55.
Evans, C.H.: Leukoregulin. Prog. Clin. Biol. Res., 288:259-270, 1988.
56.
Barnett, S.C., Evans, C.H.: Leukoregulin induced translocation of protein kinase
C activity in K562 cells. Clin. Exptl. Immunol., 73:505-509, 1988.
57.
Evans, C.H., Baker, P.D.: Tumor-inhibitory antibiotic uptake facilitated by
leukoregulin: A new approach to drug delivery. J. Natl. Cancer Inst., 80:861-864,
1988.
58.
Sheehy, P.A., Barnett, S.C., Evans, C.H., Barker, J.L.: Activation of ion channels
in tumor cells by leukoregulin, a cytostatic lymphokine. J. Natl. Cancer Inst.,
80:868-871, 1988.
59.
Evans, C.H., DiPaolo, J.A.: Chemico-biological interactions in the immunologic
modulation of initiated and promoted transformation. In Elmore, E.L.,
Langenbach, R.J. and Barrett, J.C. (Eds.): Tumor Promoters: Biological
CV CH Evans 14
Approaches for Mechanistic Studies and Assays., New York, N.Y., Raven Press,
1988, pp. 179-186.
60.
Evans, C.H.: Mechanisms of leukoregulin anti-cancer action. In Ransom, J.H.
and Ortaldo, J. (Eds.): Leukolysins and Cancer: Biological and Chemical
Aspects, Clifton, N.J., The Humana Press, Inc., 1988, pp. 198-216.
61.
Borden, E.C., Bradley, E.C., Evans, C.H., Fox, C.F., Metzgar, R.S., Mitchell,
M.S., Weinstein, J.N.: Biotechnology products in cancer therapy: A colloquium.
Cancer Res., 48:223-225, 1988.
62.
Evans, C.H., Heinbaugh, J.A., Ransom, J.H.: Flow cytometric evaluation of
leukoregulin as an intrinsic molecular mediator of natural killer lymphocyte
cytotoxicity. Lymphokine Res., 6:277-297, 1987.
63.
Evans, C.H., Barnett, S.C.: Comparative chromatography of lectins and
bioactivity recovery of the immunologic hormone leukoregulin on derivatized
silica and on cross-linked agarose molecular sizing HPLC matrices. J.
Chromatogr., 390:391-400, 1987.
64.
vans, C.H.: ASA’s 1986 Garden State party. The Azalean, 8:561-52, 1986.
65.
Evans, C.H., Barnett, S.C.: Leukoregulin transmembrane signals and regulation
of cell growth. In Bonavida, B., Collier, J.R. (Eds).: Membrane Mediated
Cytotoxicity, UCLA Symposia on Molecular and Cellular Biology, New Series,
Volume 45. New York, Alan R. Liss, Inc., 1986, pp. 423-437.
66.
Barnett, S.C., Evans, C.H.: Leukoregulin increased plasma membrane
permeability and associated ionic fluxes. Cancer Res., 46:2686-2692, 1986.
67.
Das, K.K., Basu, M., Basu, S., Evans, C.H.: Biosynthesis in vitro of GalNAc
ß1-3-containing globoside and Forssman glycolipid by two
N-acetylgalactosaminyl-transferases from chemically transformed guinea pig
cells. Carbohydrate Res., 149:119-135, 1986.
68.
Evans, C.H.: Come alive in ‘85- A Mobile chronicle. The Azalean, 7:49-51, 1985.
69.
Evans, C.H.: 1985 Guide to azalea hardiness. The Azalean, 7:78-83, 1985.
70.
Evans, C.H. and Miller W. C. III: Pattern of sporting. The Azalean, 7:1-2, 1985.
71.
Ransom, J.H., Evans, C.H., McCabe, R.P., Hanna, M.G., Jr.: The mechanism of
leukoregulin enhancement of target cell susceptibility to NK cell mediated
cytotoxicity in humans. In Henkart, P. (Ed.): Mechanisms in Cell Mediated
Cytotoxicity II. New York, Plenum Publ. Co., 1985, pp. 281-287.
CV CH Evans 15
72.
Barnett, S.C., Evans, C.H.: Membrane permeability changes induced by the
anti-tumor lymphokine leukoregulin. In Hellman, K. and Eccles, S.A. (Eds.):
Treatment of Metastasis, Problems and Prospects. London, Taylor and Frances,
1985, pp. 295-298.
73.
DiPaolo, J.A., Doniger, J., Evans, C.H., and Popescu, N.C.: Enhancement and
inhibition of transformation of Syrian hamster embryo cells. Carcinog. Compr.
Surv., 8:319-328, 1985.
74.
Ransom, J.H., Evans, C.H., McCabe, R.P., Pomato, N., Heinbaugh, J.A., Chin,
M., Hanna, M. G., Jr.: Leukoregulin, a direct-acting anti-cancer immunologic
hormone that is distinct from lymphotoxin and interferon. Cancer Res.,
45:851-862, 1985.
75.
Evans, C.H.: Origins of the evergreen hybrids Ben Morrison and B. Y. Morrison.
The Azalean, 6:11-12, 1984.
76.
DiPaolo, J.A., Doniger, J., Popescu, N.C., Evans, C.H.: Modulation of radiation
induced transformation by combinations of a phorbol diester and a lymphotoxin.
Toxicologic Path., 12:168-172, 1984.
77.
McCabe, R.P., Oneson, R., Evans, C.H.: Mechanism of natural delayed-type
hypersensitivity reactions to tumor cells in nonimmunized syngeneic guinea pigs.
Cancer Immunol. Immunother., 17:76-82, 1984.
78.
Sukamar, S., Pulciani, S., Doniger, J., DiPaolo, J.A., Evans, C.H., Zbar, B.,
Barbacid, M.: A transforming ras gene in tumorigenic guinea pig cell lines
initiated by diverse chemical carcinogens. Science, 223:1197-1199, 1984.
79.
McCabe, R.P., Evans, C.H.: Secretion of proteinase inhibitors by tumorigenic
and non-tumorigenic guinea pig and Syrian hamster fibroblasts: evidence for
autocrine regulation of local proteolysis. Cancer Res., 44:1392-1397, 1984.
80.
DiPaolo, J.A., Evans, C.H., DeMarinis, A.J., Doniger, J.: Inhibition of
radiation-initiated and -promoted transformation of Syrian hamster embryo cells
by lymphotoxin. Cancer Res., 44:1465-1471, 1984.
81.
Evans, C.H., Ransom, J.H.: The anti-cancer action of lymphotoxin. In Goldstein,
A. L. (Ed.): Thymic Hormones and Lymphokines. New York, Plenum Publ. Co.,
1984, pp. 357-364.
82.
Evans, C.H.: Normal levels of lymphotoxin secretion by freshly isolated and
refrigerated human peripheral blood lymphocytes. J. Immunol. Meth., 67:13-20,
1984.
CV CH Evans 16
83.
Evans, C. H.: Azalea potting and growing mixes: Recipes from growers coast to
coast. The Azalean, 5:60-64, 1983.
84.
Ransom, J.H., Evans, C.H.: Molecular and biological characterization of
anticarcinogenic and tumor cell growth-inhibitory activities of Syrian hamster
lymphotoxin. Cancer Res., 43:5222-5227, 1983.
85.
Ransom, J.H., Pintus, C., Evans, C.H.: Lymphotoxin amplification of tumor
growth inhibition is specific for natural killer cells not macrophages. Int. J.
Cancer, 02:93-97, 1983.
86.
Ransom, J.H., Evans, C.H., Jones, A.E., Zoon, R.A., DiPaolo, J.A.: Control of
the carcinogenic potential of 99mtechnetium by the immunologic hormone
lymphotoxin. Cancer Immunol. Immunother., 15:126-130, 1983.
87.
Evans, C.H.: Lymphokines, homeostasis, and carcinogenesis. J. Natl. Cancer
Inst., 71:253-258, 1983.
88.
McCabe, R.P., Evans, C.H., DiPaolo, J.A.: Relationship of neoantigens induced
by 3-methylcholanthrene treatment of Syrian hamster embryo cells to antigens
expressed on fetal and 3-methylcholanthrene transformed neoplastic cells.
Oncodevelop. Biol., 4:383-393, 1983.
89.
Pintus, C., Ransom, J.H., Evans, C.H.: Endothelial cell growth supplement: A
cell cloning factor that promotes the growth of monoclonal antibody producing
hybridoma cells. J. Immunol. Meth., 61:195-200, 1983.
90.
Fuhrer, J.P., Evans, C.H.: The anticarcinogenic and tumor growth inhibitory
activities of lymphotoxin are associated with altered membrane glycoprotein
synthesis. Cancer Lett., 19:283-292, 1983.
91.
McCabe, R.P., Evans, C.H.: The regulatory role of extracellular proteases in
tumor growth. Surv. Synth. Path. Res., 2:1-9, 1983.
92.
Evans, C.H., Heinbaugh, J.A., DiPaolo, J.A.: Comparative effectiveness of
lymphotoxin anticarcinogenic and tumor cell growth inhibitory activities. Cell.
Immunol., 76:295-303, 1983.
93.
Fuhrer, J.P., Evans, C.H., Ransom, J.H., Heinbaugh, J.A.: Identification of
lymphotoxin as the predominant molecular class of in vitro and in vivo Syrian
hamster lymphotoxin. Cell. Immunol., 75:63-70, 1983.
94.
Greiner, J.W., Evans, C.H., DiPaolo, J.A.: Carcinogen-induced phenotypic
alterations in mammary epithelial cells accompanying the development of
neoplastic transformation. Cancer Res., 43:273-278, 1983.
CV CH Evans 17
95.
Basu, S., Basu, M., Higashi, H., Evans, C.H.: Biosynthesis and characterization
of globoside and Forrsman glycosphingolipids in guinea pig tumor cells. In: A.
Makita, S. Handa, T. Taketomi and Y. Nagai, (Eds.): New Vistas in Glycolipid
Research. New York, Plenum Publishing Corp., 1982, pp. 131-137.
96.
DiPaolo, J.A., Evans, C.H., DeMarinis, A.J., Doniger, J.: Phytohemagglutinin
inhibits phorbol diester promotion of UV irradiation initiated transformation in
Syrian hamster embryo cells. Int. J. Cancer, 30:781-786, 1982.
97.
DiPaolo, J.A., Evans, C.H., Milo, G.E.: The susceptibility of normal hamster and
human cells to transformation by environmental agents. In Armstrong, B., and
Bartsch, H. (Eds.): Host Factors in Human Carcinogenesis, Lyon, IARC
Scientific Publications, pp. 561-569, 1982.
98.
Evans, C.H., DiPaolo, J.A.: Independent expression of chemical
carcinogen-induced phenotypic properties frequently associated with the
neoplastic state in a cultured guinea pig cell line. J. Natl. Cancer Inst.,
69:1175-1182, 1982.
99.
Fuhrer, J.P., Evans, C.H.: Rapid separation of biologically active Syrian hamster
lymphotoxin in high yield by size exclusion high performance liquid
chromatography. J. Chromatog., 248:427-433, 1982.
100.
Greiner, J.W., Evans, C.H.: Temporal dynamics of cortisol and dexamethasone
prevention of benzo(a)pyrene-induced morphological transformation of Syrian
hamster cells. Cancer Res., 42:4014-4017, 1982.
101.
Ransom, J.H., Evans, C.H., DiPaolo, J.A.: Lymphotoxin prevention of
diethylnitrosamine carcinogenesis in vivo. J. Natl. Cancer Inst., 69:741-744,
1982.
102.
Evans, C.H., DiPaolo, J.A., Heinbaugh, J.A., DeMarinis, A.J.:
Immunomodulation of the lymphoresponsive phases of carcinogenesis by
natural immunity. J. Natl. Cancer Inst., 69:737-741, 1982.
103.
Ransom, J.H., Evans, C.H.: Lymphotoxin enhances the susceptibility of
neoplastic and preneoplastic cells to natural killer cell mediated destruction. Int.
J. Cancer, 29:451-458, 1982.
104.
Evans, C.H., Boynton, A.L.: Calcium dependence of chemical carcinogen
induced morphological transformation of Syrian hamster embryo cells. Cancer
Lett., 15:271-279, 1982.
105.
Evans, C.H.: Lymphotoxin--an immunologic hormone with anticarcinogen and
antitumor activity. Cancer Immunol. Immunother., 12:181-190, 1982.
CV CH Evans 18
106.
Ransom, J.H., Rundell, J.O., Heinbaugh, J.A., Evans, C.H.: Biological and
physicochemical characterization of keyhole limpet hemocyanin-induced guinea
pig lymphotoxin. Cell. Immunol., 67:1-13, 1982.
107.
McCabe, R.P., Evans, C.H.: Relationship of plasminogen activator, fibronectin
production, sensitivity to lymphotoxin cytotoxicity, and natural delayed-type skin
reactivity to tumorigenicity of chemical carcinogen transformed guinea pig cells.
J. Natl. Cancer Inst., 68:329-336, 1982.
108.
Evans, C.H., DiPaolo, J.A.: Equivalency of endothelial cell growth supplement to
irradiated feeder cells in carcinogen induced morphological transformation of
Syrian hamster embryo cells. J. Natl. Cancer Inst., 68:127-132, 1982.
109.
DiPaolo, J.A., Evans, C.H., Popescu, N.C., Doniger, J.N.: Regulation of
mammalian cell transformation. In Hecker, E. (Ed.): Cocarcinogenesis and
Biological Effects of Tumor Promoters, Vol. 7, New York, Raven Press, 1982, pp.
273-276.
110.
DiPaolo, J.A., DeMarinis, A.J., Evans, C.H., Doniger, J.: Expression of initiated
and promoted stages of irradiation carcinogenesis in vitro. Cancer Lett.,
14:243-249, 1982.
111.
Evans, C.H., Heinbaugh, J.A.: Lymphotoxin cytotoxicity, a combination of
cytolytic and cytostatic cellular responses. Immunopharmacology, 3:347-359,
1981.
112.
Ohanian, S.O., McCabe, R.P., Evans, C.H.: Immunogenicity of guinea pig cells
transformed in culture by chemical carcinogens. J. Natl. Cancer Inst.,
67:1363-1368, 1981.
113.
Shu, S., Steerenberg, P.A., Hunter, J.T., Evans, C.H., Rapp, H.J.: Adoptive
immunity to the guinea pig line 10 hepatoma and the nature of in vitro
lymphoid-tumor cell interactions. Cancer Res., 41:3499-3506, 1981.
114.
Evans, C.H.: The role of lymphotoxin in natural cell-mediated cytotoxicity. Cell.
Immunol., 63:1-15, 1981.
115.
Greiner, J.W., Evans, C.H., DiPaolo, J.A.: Carcinogen-induced
anchorage-independent growth and in vivo lethality of human MRC-5 cells.
Carcinogenesis, 2:359-363, 1981.
116.
Evans, C.H., DiPaolo, J.A.: In vitro mammalian cell transformation for
identification of carcinogens, cocarcinogens, and anticarcinogens. In Stich, H.
and San, R. H. C. (Eds.): Short-Term Tests for Chemical Carcinogens,
Springer-Verlag, New York, 1981, pp. 306-322.
CV CH Evans 19
117.
Evans, C.H., Greiner, J.W.: Corticosteroid prevention of carcinogenesis in
benzo(a)pyrene or ultraviolet irradiation treated Syrian hamster cells in vitro.
Cancer Lett., 12:23-27, 1981.
118.
Evans, C.H., DiPaolo, J.A.: Lymphotoxin: an anticarcinogenic lymphokine as
measured by inhibition of chemical carcinogen or ultra-violet irradiation induced
transformation of Syrian hamster cells. Int. J. Cancer, 27:45-49, 1981.
119.
Rundell, J.O., Evans, C.H.: Species specificity of guinea pig and human
lymphotoxin colony inhibitory activity. Immunopharmacology, 3:9-18, 1981.
120.
Sisskin, E.E., Weinstein, I.B., Evans, C.H., DiPaolo, J.A.: Plasminogen activator
synthesis accompanying chemical carcinogen-induced in vitro transformation of
Syrian hamster and guinea pig fetal cells. Int. J. Cancer, 26:331-336, 1980.
121.
Rundell, J.O., Evans, C.H.: Biological characterization of guinea pig lymphotoxin
production. Immunopharmacology, 2:19-27, 1979.
122.
Evans, C.H.: Neoplastic transformation by chemicals of guinea pig fetal cells in
culture. In Saffiotti, U., and Autrup, H. (Eds.): In Vitro Carcinogenesis. Guide to
the Literature, Recent Advances and Laboratory Procedures. National Cancer
Institute Carcinogenesis Technical Report Series No. 44 (1978), DHEW Pub. No.
(NIH) 78-844, U.S. Gov't Printing Office, Washington, D. C., pp. 82-83.
123.
Evans, C.H., Rabin, E.S., DiPaolo, J.A.: The susceptibility of guinea pig cells to
the colony inhibitory activity of lymphotoxin during carcinogenesis. Cancer Res.,
37:898-903, 1977.
124.
Zbar, B., Ribi, E., Kelly, M., Granger, D., Evans, C.H., Rapp, H.J.: Immunologic
approaches to the treatment of human cancer based on a guinea pig model.
Cancer Immunol. Immunother., 1:127-138, 1976.
125.
Basu, M., Basu, S., Shanabruch, W.G., Moskal, J.R., Evans, C.H.: Lectin and
cholera toxin binding to guinea pig tumor (104C1) cell surfaces before and after
glycospingolipid incorporation. Biochem. Biophys. Res. Commun., 71:385-392,
1976.
126.
Popescu, N.C., Evans, C.H., DiPaolo, J.A.: Chromosome patterns (G and C
bands) of in vitro chemical carcinogen-transformed guinea pig cells. Cancer
Res., 36:1404-1413, 1976.
127.
Evans, C.H., DiPaolo, J.A.: Comparison of nude mice with the host species for
evaluation of the tumorigenicity of guinea pig and hamster cells transformed in
vitro by chemical carcinogens. Cancer Res., 36:128-131, 1976.
CV CH Evans 20
128.
Evans, C.H., DiPaolo, J.A.: Properties of cells from different mammalian species
accompanying chemical carcinogen induced transition to the neoplastic state.
Proc. XI Inter. Cancer Congress, Florence, 1974. Excerpta Medica International
Congress Series, Amsterdam, 1975, pp. 118-121.
129.
Hsiung, G.D., Fong, D.K.Y., Evans, C.H.: Prevalence of endogenous
oncornavirus in guinea pigs. Intervirology, 3:319-331, 1975.
130.
Zwilling, B.S., Meltzer, M.S., Evans, C.H.: Differential cytotoxicity of tumorigenic
and nontumorigenic strain-2 guinea pig cells mediated by syngeneic
phytohemagglutinin stimulated peritoneal exudate cells. J. Natl. Cancer Inst.,
54:743-747, 1975.
131.
Evans, C.H., Cooney, A.M., DiPaolo, J.A.: Colony inhibition mediated by
nonimmune leukocytes in vitro and skin reactivity in vivo as indices of
tumorigenicity of guinea pig cultures transformed by chemical carcinogens.
Cancer Res., 35:1045-1052, 1975.
132.
Evans, C.H., DiPaolo, J.A.: Neoplastic transformation of guinea pig fetal cells in
culture induced by chemical carcinogens. Cancer Res., 35:1035-1044, 1975.
133.
Evans, C.H., Ohanian, S.H., Cooney, A.M.: Tumor specific and Forssman
antigens of guinea pig hepatoma cells: comparison of tumor cells grown in vivo
and in vitro. Int. J. Cancer, 15:512-521, 1975.
134.
Olinici, C.D., Evans, C.H., DiPaolo, J.A.: Chromosome patterns of
nontransformed variants from chemical transformed Balb/3T3 cells. J. Cell.
Physiol., 83:401-408, 1974.
135.
Evans, C.H., DiPaolo, J.A.: Mammalian cells for carcinogen identification. J.
Am. Med. Assoc., 225:631-632, 1973.
136.
DiPaolo, J.A., Nelson, R.L., Donovan, P.J., Evans, C.H.: Host-mediated in vivo in vitro assay for chemical carcinogenesis. Arch. Path., 95:380-385, 1973.
137.
Atuk, N.O., Evans, C.H.: Hypertension as a localizing sign of mass lesions of
brainstem. N. Eng. J. Med., 287:1355-1356, 1972.
138.
Evans, C.H., Westfall, V., Atuk, N.O.: Astrocytoma mimicking the features of
pheochromocytoma. N. Eng. J. Med., 286:1397-1399, 1972.
139.
Evans, C.H.: Fluorescein isothiocyanate probing of human immunoglobulin G.
Thesis, University of Virginia Library, 1969.
140.
Evans, C.H., Herron, S.B., Goldstein, G.: Antibody activity associated with the
fuorescent polypeptide chains of human immunoglobulin G. J. Immunology,
CV CH Evans 21
101:915-923, 1968.
May 2008